Recent News

• 05.26.2026 - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
• 05.12.2026 - Phio Pharmaceuticals Announces “Innovations in Skin Cancer Treatment and Prevention” in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
• 05.07.2026 - Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
• 04.23.2026 - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
• 04.13.2026 - Phio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
• 04.09.2026 - Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
• 03.30.2026 - Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
• 03.23.2026 - Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
• 03.16.2026 - Phio Pharmaceuticals Announces “A Groundbreaking Approach to Treating Skin Cancer” in a Fireside Chat with Force Family Office
• 03.10.2026 - Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

Recent Filings

• 05.07.2026 - 8-K Current report
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - EX-99.1 EX-99.1
• 04.08.2026 - 8-K Current report
• 04.08.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.30.2026 - 8-K Current report
• 03.05.2026 - EX-99.1 EX-99.1
• 03.05.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]